Evidence map›Paper›PMID 35073955›Full record

ArticleRadiation oncology (London, England)2022

Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.

Vivien N Sommerlath, Daniel Buergy, Nima Etminan, Stefanie Brehmer, David Reuss, Gustavo R Sarria, Marie-Christin Guiot, Daniel Hänggi, Frederik Wenz, Kevin Petrecca and 1 more

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Brain tumour genetic network signatures of survival.Brain : a journal of neurology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vivien N Sommerlath *Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany.
Daniel Buergy *Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany.
Nima EtminanDepartment of Neurosurgery, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany.
Stefanie BrehmerDepartment of Neurosurgery, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany.
David ReussDepartment of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Gustavo R SarriaDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Marie-Christin GuiotDepartment of Pathology, Montreal Neurological Institute, Montreal, Canada.
Daniel HänggiDepartment of Neurosurgery, Heinrich-Heine-Universität, Düsseldorf, Germany.
Frederik WenzFreiburg Medical Center, Freiburg, Germany.
Kevin PetreccaDepartment of Neurosurgery, Montreal Neurological Institute, Montreal, Canada.
Frank A GiordanoDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. frank.giordano@ukbonn.de.ORCID http://orcid.org/0000-0001-5243-4781

Funding

Deutsche Forschungsgemeinschaft SFB1389 (UNITE Glioblastoma)
6 · The paper itself

Abstract

backgroundAlthough glioblastoma (GB) is associated with a devastating prognosis, a small proportion of patients achieve long-term survival rates. We herein present a matched-pair analysis of molecular factors found in long- and short-term survivors (LTS, STS).

methodsWe performed a cross-institutional analysis of 262 patient records and matched a group of 91 LTS (≥ 3 years) with two groups of STS (STS-1, n = 91; STS-2, n = 80). Matching was performed according to age, Karnofsky Performance Status, initial therapy and adjuvant therapy. Molecular factors were compared between LTS (total of 91 patients) v. STS-1, and LTS (subgroup of 80 patients) v. STS-2. We included glial fibrillary acidic protein (GFAP), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, isocitrate dehydrogenase 1 (IDH-1); furthermore, the proliferation index was analyzed (Ki-67/MIB-1).

resultsIDH-1 and decreased Ki-67 were numerically associated with LTS but the difference was only significant compared to STS-1 (n.s. v. STS-2). LTS was associated with MGMT promoter hypermethylation (p = 0.013 and p = 0.022) and GFAP expression (p < 0.001 and p = 0.001). Positivity for both factors combined compared to negativity for one factor occurred more often in the LTS group (p = 0.002 and p = 0.006); negativity for both factors combined did not occur in the LTS group.

conclusionIn this retrospective analysis, GFAP expression and MGMT promoter methylation were associated with LTS. Given the hypothesis-generating nature of our study, these observations should be confirmed in prospective clinical trials.

Indexed as

AdolescentAdultAgedAged, 80 and overCancer SurvivorsChildDNA Modification MethylasesDNA Repair EnzymesFemaleGene Expression Regulation, NeoplasticGlial Fibrillary Acidic ProteinGlioblastomaHumansMaleMatched-Pair AnalysisMiddle AgedDNA Modification MethylasesDNA Repair EnzymesGFAP protein, humanGlial Fibrillary Acidic ProteinMGMT protein, humanTumor Suppressor ProteinsGBMGFAPGlioblastomaMGMTPrognostic factors

Identifiers

PMID35073955
PMCPMC8785532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.